Shares of Pozen rallied 16 percent on news that the FDA had accepted its amended response for the experimental migraine drug Trexima. The amendment was filed in February after Trexima was rejected in December. Pozen has been working with GlaxoSmithKline to gain an approval on Trexima, a combination of Glaxo's Imitrex and the anti-inflammatory naproxen.
- read Pozen's release
- here's the report from LocalTechWire